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Abstract
Objective: Donepezil, an inhibitor of acetylcholinesterase (AChE) targeting the
brain, is a common medication for Alzheimer's disease. Interestingly, a recent
clinical study found that administration of this agent is associated with lower
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risk of hip fracture independently of falling, suggesting its direct effect on bone
tissues as well. AChE has been reported to be involved in osteoblast function,
but the role of AChE on osteoclastogenesis still remains unclear. We analyzed
the effect of AChE and donepezil on osteoclastogenesis [45_TD$DIFF]in vivo and in vitro.
Methods: Cell-based assays were conducted using osteoclasts generated in
cultures of murine bone marrow macrophages (BMMs) with receptor activator
of nuclear factor-kappa B ligand (RANKL). The effect of donepezil was also
determined [46_TD$DIFF]in vivo using a mouse model of RANKL-induced bone loss.
Results: Recombinant AChE in BMMs cultured with RANKL further
promoted RANKL-induced tartrate-resistant acid phosphatase (TRAP)-positive
osteoclast differentiation. RANKL also upregulated AChE expression in
BMMs. RNA interference-mediated knockdown of AChE significantly
inhibited RANKL-induced osteoclast differentiation and suppressed gene
expression specific for osteoclasts. AChE upregulated expression of RANK,
the receptor of RANKL, in BMMs. Donepezil decreased [47_TD$DIFF]cathepsin K
expression in BMMs and the resorptive function of osteoclasts on dentine
slices. Donepezil decreased RANK expression in BMMs, resulting in the
inhibition of osteoclast differentiation with downregulation of c-Fos and
upregulation of Id2. Moreover, administration of donepezil prevented
RANKL-induced bone loss [48_TD$DIFF]in vivo, which was associated with the inhibition
of bone resorption by osteoclasts.
Conclusions: AChE promotes osteoclast differentiation [49_TD$DIFF]in vitro. Donepezil
inhibits osteoclast function [50_TD$DIFF]in vitro and prevents bone loss by suppressing
bone resorption [48_TD$DIFF]in vivo, suggesting the possibility that donepezil reduces
fracture risk in patients with Alzheimer's disease.
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1. Introduction
Bone is continuously renewed in a balanced alternation by osteoclasts and
osteoblasts [1]. Hemopoietic cells of the monocytes/macrophage lineage
differentiate into osteoclasts, which are capable of resorbing bone under the
control of macrophage colony-stimulating factor (M-CSF) and receptor activator
of nuclear factor-κB ligand (RANKL), both of which are generated by
osteoblastic cells in bone tissues [2]. The expression of RANK, the receptor of
RANKL, in osteoclast precursors is required for RANKL-induced osteoclast
differentiation. After RANKL binds to RANK, the transcription factor c-Fos is
upregulated for activating nuclear factor of activated T-cells, cytoplasmic 1
( [51_TD$DIFF]NFATc1), the master regulator for osteoclast differentiation, leading to the
expression of genes specific for osteoclasts, such as tartrate-resistant acid
phosphatase (TRAP) and [52_TD$DIFF]cathepsin K [3].
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Donepezil, which is an inhibitor of acetylcholinesterase (AChE) and thereby leads
to increased concentrations of acetylcholine in the brain, is widely used for the
treatment of patients with Alzheimer's disease [4]. Of note, recent clinical data
suggested that donepezil administration dose-dependently reduced the increased
risk of hip fracture independently of falling in patients with Alzheimer's disease
[5]. Although donepezil can easily cross the blood-brain barrier and acts centrally
in the brain, the half-life of donepezil in humans has been known to be around
3 days, suggesting that donepezil may act directly on bone cells as well [6]. Thus,
it is possible to speculate that donepezil has a dual function in affecting bone mass
peripherally as well as centrally.
AChE, which rapidly hydrolyzes the neurotransmitter acetylcholine in synapses
and neuromuscular junction, has been detected in various cells such as
hematopoietic, osteogenic and neoplastic cells [31_TD$DIFF] 7] [8] [9] [10]. Several lines of
evidence have shown that AChE has non-hydrolytic functions as well, besides its
well-known action as a hydrolytic enzyme of acetylcholine [10]. Axonal and
neurite growth is regulated by AChE without hydrolytic activity in chick nerve
cells [11], and the neurite outgrowth-promoting effect of AChE was associated
with a non-catalytic mechanism in chick sympathetic neurons [7]. The rate of
oxygen consumption in macrophages is increased by stimulating AChE
independent of catalytic activity [12].
Recent evidence has indicated that AChE is involved in the function of osteoblasts.
For instance, AChE mRNA variant 3′ terminated with exon 6 expression is
increased with osteoblast differentiation, whereas its suppression increases the
proliferation rate in human osteosarcoma cells [13]. Furthermore, Genever and his
colleagues demonstrated that AChE is a novel osteoblast-derived mediator of
cell-matrix interactions [32_TD$DIFF] 14] [15]. Although AChE is also expressed in
macrophages and osteoclasts as well [33_TD$DIFF] 16] [17], the function of AChE in osteoclasts
has not been examined before.
We hypothesized that AChE may be directly involved in osteoclastic
differentiation. In this report, we investigated whether AChE and donepezil affect
differentiation and function of osteoclasts [49_TD$DIFF]in vitro. To examine this possibility,
cell-based assays were conducted using osteoclasts generated by murine bone
marrow macrophages (BMMs) treated with RANKL. The effect of donepezil was
also determined [46_TD$DIFF]in vivo using a mouse model of RANKL-induced bone loss.
2. Methods
2.1. Animals
All mice (C57BL/6) were obtained from Tokyo Laboratory Animals Science,
and were kept on a normal laboratory chow in an environmentally controlled
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clean room at the Department of Oral and Maxillofacial Surgery, Saitama
Medical University. The experiments were conducted according to the
institutional guidelines for ethical animal experiments. To obtain the mouse
model of RANKL-induced bone loss, soluble RANKL (sRANKL, 1 mg/kg,
Oriental Yeast, Japan) was injected intraperitoneally at 24 h intervals for 3 days
into male mice (9-week-old) as previously described [18]. To evaluate the
prophylactic effect of donepezil, donepezil (2 mg/kg, Sigma-Aldrich, USA) was
injected before each injection of sRANKL three times at 24 h intervals
intraperitoneally. This dose of donepezil was selected on the basis of previous
studies [34_TD$DIFF] 19] [20] [21]. The mice were killed 90 min after the last injection.
Blood samples were collected at the time of sacrifice. Six mice were used in
each group.
2.2. Cell culture and reagents
We have obtained TRAP-positive osteoclasts according to the established
protocols [18]. We used BMMs derived from tibia of 10-week-old female mice.
BMMs were cultured in α-minimal essential medium (MEM) containing 10%
FBS incubated with 10 ng/ml of macrophage colony-stimulating factor (M-CSF,
Peprotech, USA) for 2 days. BMMs were further cultured in the presence
or absence of 100 ng/ml of RANKL. Donepezil or recombinant mouse
acetylcholinesterase (rAChE, R&D, USA) at indicated concentrations were added
at the same time with RANKL. The conditions of each experiments are as follows:
24 well plates at 300 × 104 cells per well or 48 well plates at 100 × 104 cells per
well for TRAP staining and harvest of total RNA; 8-mm chamber slides at 1 × 104
cells per well for immunocytochemistry; 96 well plates at 4 × 103 cells per well
for cell proliferation assay. For heat-inactivated AChE experiments, recombinant
AChE was heated for 3 min at 100°C prior to adding to BMMs cultures.
2.3. TRAP staining
For TRAP staining, cells were fixed with 10% formalin for 5 min to stain for
TRAP. Thereafter, they were re-fixed with ethanol:acetone (50:50 v/v) for 1 min
and incubated in acetate buffer (pH 4.8) containing naphthol AS-MX phosphate
(Sigma-Aldrich), fast red violet LB salt (Sigma-Aldrich), and 50 mM sodium
tartrate at room temperature. TRAP-positive multinucleated cells with more than
3 nuclei were counted as osteoclasts. Results are representative of at least four
independent experiments.
2.4. Cell proliferation assay
The cells were incubated in conditioned medium for the indicated times with
donepezil or rAChE. The sample cells were quantified using a Cell Titer 96
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Aqueous One Solution Cell Proliferation Assay (Promega, USA), according to
the manufacturer's instructions. The measurements are represented by means of
at least three independent experiments, with each data point based upon six
replicates.
2.5. Quantitative reverse-transcriptase polymerase chain
reaction (qPCR)
Total RNA was extracted from cells using ISOGEN (Nippon Gene, Japan) and
following qPCR was conducted as previously described [18]. For qPCR of
AChE, TaqMan-based detection was conducted using TaqMan Gene Expression
Master Mix (Thermo Fisher Scientific). TaqMan Gene Expression Assays
(Thermo Fisher Scientific) for AChE (Mm00477274_g1) and Mouse GAPDH
(Mm03302249_g1) were used. For qPCR of genes related with osteoclast
differentiation, we used SYBR green-based technique using THUNDERBIRD
SYBR qPCR Mix (TOYOBO, Japan). The gene-specific primer pairs used are
as follows: NFATc1 [53_TD$DIFF]sense, 5′-ATGCCAAATACAGCTTTCCAGTC-3′ and
NFATc1 [54_TD$DIFF]antisense, 5′-CGTCTTCCACCTCCACGTCG-3′; cathepsin K sense,
5′-CCTGGAGGGCCAACTCAAG-3′ and cathepsin K antisense,
5′-ATCTCTCTGTACCCTCTGCAT-3′; RANK sense,
5′-AGAGGCATTATGAGCATCTCG-3′ and RANK antisense,
5′-GGAGTGCACTTAGAGGACAGGT-3′; inhibitors of differentiation/DNA
binding 2 (Id2) sense, 5′-GACAGAACCAGGCGTCCA-3′ and Id2 [54_TD$DIFF]antisense,
5′-AGCTCAGAAGGGAATTCAGATG-3′; β-actin sense,
5′-AGAAGGACTCCTATGTGGGTGA-3′ and β-actin antisense,
5′-CATGATCTGGGTCATCTTTTCA-3′. For qPCR analysis, values were
normalized to β-actin or GAPDH using the [25_TD$DIFF] _ΔΔCt method. The measurements
are represented by the means of at least three independent experiments, with
each data point based upon triplicates.
2.6. Western blot analysis
Western blot analysis was performed as described previously [18]. We used
anti-AChE rabbit polyclonal antibody (sc-11409, Santa Cruz, USA), anti-c-Fos
rabbit monoclonal antibody (#2250, Cell Signaling, USA), and anti-Id2 rabbit
polyclonal antibody (sc-489, Santa Cruz) as primary antibodies. Anti-rabbit IgG
HRP-linked antibody (#7074, Cell Signaling) and donkey anti-mouse IgG-HRP
(sc-2314, Santa Cruz) were used as secondary antibodies. Anti-β-actin mouse
monoclonal antibody (sc-47778, Santa Cruz) was used as a loading control.
Similar independent experiments were repeated at least three times.
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2.7. Measurement of serum deoxypyridinoline (DPD)
cross-links
The serum DPD cross-links was measured by Mouse DPD assay kit
(CSB-E08401m, CUSABIO, China). The measurements are represented by the
means of at least three independent experiments, with each data-point based
upon six replicates.
2.8. Retroviral infection
To generate retrovirus stock, PLATINUM Select shRNA-mir Series retroviral
vectors (pMX, pMX-shAChE, transOMIC technologies, USA) were transfected
into the packaging cell line Plat-E using CaCl2 [22]. Supernatant was collected
from the virus culture media 48 h after transfection and filtered through a
0.45-μm filter. BMMs were incubated with virus supernatant for 12 h in the
presence of polybrene (8 μg/ml). After removing the virus supernatant, BMMs
were incubated in the presence of M-CSF and RANKL for 5 days.
2.9. High performance liquid chromatography (HPLC)
To measure serum concentration of donepezil, HPLC was used. 100 μl of the
serum sample was gathered in 1.5 ml tube and 70 μl of CH3CN was carefully
put in the ample solution. The solution was mixed well by using a sonicator.
Then, the sample tube was left sitting for three hours on ice and the tube was
centrifuged for three hours by 12,000 g. 100 μl of the supernatant was filtered
by using a spin column cut by molecular weight of 10,000 and the filtered
liquid centrifugal was evaporated. A dried sample was dissolved with 100 μl
of Solvent A and the whole quantity of the solution was applied to HPLC. The
condition for HPLC was as follows: solvent A (0.1% TFA in H2O); solvent
B (0.1% TFA in CH3CN); column (Wako C18 for PTH amino acid); column
temperature (35°C); flow rate (0.7 ml/min); wavelength of detection (271 nm).
All samples were examined in duplicate assays.
2.10. Immunocytochemistry
For immunofluorescence, cells were fixed in 4% paraformaldehyde for 10 min
at room temperature, rinsed in phosphate-buffered saline (PBS), then permeated
for 5 min on ice. After blocking with 1% BSA solution, anti-AChE rabbit
polyclonal antibody (sc-11409, Santa Cruz, USA) as primary antibody was
incubated with specimens. Then Alexa Fluor568 goat anti-rabbit IgG (#A11011,
Thermo Fisher Scientific) was used as secondary antibody and subsequently
mounted in Vectashield Mounting Medium with DAPI (Vector Laboratories,
USA). Similar independent experiments were repeated at least three times.
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To detect apoptosis of osteoclasts, the fluorescein-dUTP TUNEL assay (In Situ
Cell Death Detection Kit, Fluorescein, Roche Applied Science, USA) was
conducted. Briefly, cells were fixed in 4% paraformaldehyde for 10 min at room
temperature and then rinsed in PBS and then permeabilized for 5 min on ice before
labelling with 50 μl of TUNEL reaction mixture and incubating at 37 °C for 1 h in
a humidified chamber under parafilm coverslips. After washing with PBS, slides
were mounted in MobiGLOW Mounting Medium. Cells were counted under
fluorescence microscopy. Samples were run in six replicates for each condition
tested.
2.11. Histological and histomorphometric analyses
Mice given soluble PBS, RANKL, and/or donepezil were injected with calcein
(25 mg per kg of body weight; Sigma) intraperitoneally 4 days and 1 day before
sacrifice. After vertebrae were fixed in 4% paraformaldehyde and dehydrated by
ethanol, they were embedded in methylmethacrylate. The plastic blocks were
trimmed and 4 or 7 μm-thick sections were prepared with a RM2255 (Leica
Microsystems). Undecalcified sections of the lumbar vertebrae were stained for
von Kossa, Toluidine Blue and TRAP staining. Static and dynamic
histomorphometric analyses were performed using OsteoMeasure Analysis System
(OsteoMetrics) following nomenclature defined by the American Society for Bone
and Mineral Research (ASBMR). Bone volume/tissue volume (BV/TV; %), bone
formation rate/bone surface (BFR/BS; μm3/μm2/year), mineral apposition rate
(MAR; μm/year), osteoblast surface (Ob.S/BS; %) and osteoclast number/bone
perimeter (No.Oc/B.Pm; per 100 mm) were analysed. Six mice were examined for
each group.
2.12. Statistical analysis
Comparisons between two groups were analyzed using Student's t-tests and
comparisons among three groups were analyzed using One-Way Analysis of
Variance and Bonferroni/Dunn methods (#, p < 0.05; ##, p < 0.01). All values
are represented as the mean ± S.E.M.
3. Results
3.1. AChE accelerates RANKL-induced osteoclast
differentiation, and RANKL upregulates endogenous AChE
concentration in BMMs
We hypothesized that AChE plays a vital role in osteoclast differentiation and
function [49_TD$DIFF]in vitro. To examine this hypothesis, recombinant AChE was added
at 50, 100, and 200 ng/ml to BMMs cultures in the presence of RANKL.
Cultures were conducted for 5 days in the presence of RANKL and M-CSF.
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[(Fig._1)TD$FIG]
Fig. 1. AChE promotes RANKL-induced osteoclast differentiation of BMMs, and RANKL
upregulates endogenous AChE. A, Effect of rAChE (0, 50, 100, and 200 ng/ml) on osteoclast
differentiation of BMMs: (upper panel) TRAP staining (Scale bar, 1.0 mm), (lower panel) number
of TRAP-positive multinucleated cells formed (more than 3 nuclei). Data are calculated from three
repeated experiments. B, Effect of heat-inactivated rAChE (0, 100, and 200 ng/ml) on osteoclast
differentiation of BMMs: number of TRAP-positive multinucleated cells formed (more than 3
nuclei). Data are calculated from three repeated experiments. C, Expression of AChE mRNA in
BMMs in the presence or absence of RANKL for 24 h estimated by quantitative RT-PCR analysis.
Data are calculated from three repeated experiments. D, Expression of AChE protein in BMMs in
the presence or absence of RANKL for 48 h estimated by Western blot analysis. Data are calculated
from three repeated experiments. rAChE, recombinant acetylcholinesterase; RANKL, receptor
activator of nuclear factor-κB ligand; BMMs, bone marrow macrophages; TRAP, tartrate-resistant
acid phosphatase; #, p < 0.05; ##, p < 0.01. Data are expressed as the means ± S.D.
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RANKL-induced TRAP-positive cell formation was significantly increased when
rAChE was added at 100 and 200 ng/ml in a dose-dependent manner (Fig. 1A).
Expression of both NFATc1 [26_TD$DIFF]and cathepsin K was also upregulated significantly
by adding 100 ng/ml of rAChE (Supplementary Fig. S1A). To confirm that the
increase of TRAP-positive cell formation is not due to the stimulation of cell
proliferation of BMMs, we assessed proliferation assay of BMMs cultures.
rAChE rather inhibited proliferation in BMMs cultures significantly
(Supplementary Fig. S1B).
Supplementary material related to this article is found, in the online version, at
http://dx.doi.org/10.1016/j.heliyon.2015.e00013.
We examined whether AChE promotes osteoclast differentiation independent of
enzymatic action. Heat-inactivated rAChE was added at 100 and 200 ng/ml to the
BMMs cultures treated with RANKL. Cultures were conducted for 5 days in the
presence of RANKL and M-CSF. We found that heat-inactivated AChE did not
promote RANKL-induced osteoclast formation (Fig. 1B). This result suggests that
enzymatic activity of AChE is required for promoting RANKL-induced osteoclast
differentiation.
We next conducted qPCR analysis to examine mRNA expression of AChE in
BMMs in the presence or absence of RANKL. mRNA expression of AChE was
significantly upregulated in BMMs in the presence of RANKL (Fig. 1C). Western
blot analysis showed that the expression of AChE protein was also upregulated by
RANKL stimulation (Fig. 1D). Immunofluorescence staining showed that RANKL
increased accumulation of AChE protein in BMMs compared with the control
group (Supplementary Fig. S1C). Short hairpin AChE (shAChE)-A, B or C was
retrovirally delivered to BMMs and the mRNA expression level of AChE was
verified by qPCR (Supplementary Fig. S2A). Among three subtypes of shAChE,
the subtype shAChE-A most effectively suppressed mRNA expression of AChE.
Knockdown of AChE-A in BMMs suppressed RANKL-induced TRAP-positive
cell formation (Supplementary Fig. S2B) and [58_TD$DIFF]NFATc1 expression (Supplementary
Fig. S2C). These results indicate that AChE derived from BMMs promotes
RANKL-induced osteoclast differentiation. Interestingly, treatment of BMMs with
AChE significantly upregulated mRNA expression of RANK, the receptor of
RANKL, in a time-dependent manner (Supplementary Fig. S2D).
Supplementary material related to this article is found, in the online version, at
http://dx.doi.org/10.1016/j.heliyon.2015.e00013.
3.2. Donepezil suppresses osteoclast differentiation
In order to block the signals of AChE in BMMs treated with RANKL,
donepezil, a specific inhibitor of AChE, was used. As expected, when
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donepezil was added at 0.5 and 5.0 μg/ml to BMMs cultured for 5 days in the
presence of RANKL, TRAP-positive cell formation was significantly decreased
in a dose-dependent manner (Fig. 2A). Gene expression of both NFATc1 [26_TD$DIFF]and
[(Fig._2)TD$FIG]
Fig. 2. Inhibition of osteoclast differentiation in BMMs by donepezil. A, Effect of donepezil
(0, 0.5 and 5 μg/ml) on osteoclast differentiation of BMMs: (upper panel) TRAP staining,
(lower panel) number of TRAP-positive multinucleated cells formed (Scale bar, 1.0 mm).
Data are calculated from four repeated experiments. B, mRNA expression of osteoclast-specific
genes in BMMs treated with RANKL with or without donepezil (0, 0.5 and 5 μg/ml) for 5 days
estimated by qPCR analysis: (left panel) NFATc1, (right panel) cathepsin K . Data are calculated
from three repeated experiments. #, p < 0.05; ##, p < 0.01. Data are expressed as the means ± S.D.
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cathepsin K was also dose-dependently downregulated by donepezil (Fig. 2B).
To confirm that the decrease of TRAP-positive cell formation is not due to the
inhibition of cell proliferation, we assessed whether donepezil affects cell
proliferation of BMMs. Donepezil rather increased cell proliferation in BMMs
cultures (Supplementary Fig. S3A), suggesting that the suppressing effect of
donepezil on osteoclast formation is simply not due to the inhibition of cell
proliferation.
Supplementary material related to this article is found, in the online version, at
http://dx.doi.org/10.1016/j.heliyon.2015.e00013.
3.3. Donepezil induces Id2 expression in osteoclast
differentiation
To obtain an insight into what molecule or molecules are involved in the inhibitory
effect of donepezil on osteoclast differentiation, we examined Id2, the protein
inhibitor of activated STAT3 (PIAS3), and paired box protein 6 (Pax6) mRNA
expression, since these molecules have been reported to be involved in osteoclast
differentiation as negative regulators [61_TD$DIFF] 22] [23] [24]. The mRNA expression level
of Id2 in donepezil-treated BMMs was upregulated during osteoclast
differentiation in a dose-dependent manner (Fig. 3A), whereas the levels of PIAS3 [26_TD$DIFF]
and Pax6 were not changed appreciably (data not shown). The level of Id2 protein
was also upregulated in a similar manner (Fig. 3B). mRNA expression of Id2 was
not changed at 9 h but it was greatly upregulated at 24 h after stimulation by
donepezil (Supplementary Fig. S3B). Furthermore, the level of c-Fos protein,
which plays an essential role for osteoclast differentiation [25], was downregulated
by donepezil in a dose-dependent manner (Fig. 3B). We then examined whether
donepezil affects RANK expression of BMMs, since mRNA expression of RANK
was upregulated when BMMs were cultured with 100 ng/ml of rAChE
(Supplementary Fig. S2D). Expectedly, mRNA expression of RANK in BMMs
was downregulated by adding donepezil in a time-dependent manner (Fig. 3C).
These results suggest that donepezil directly inhibits osteoclast differentiation, in
accompanied with the Id2 upregulation and c-Fos downregulation.
It is not known whether AChE promotes RANKL-induced osteoclast formation
by degradation of acetylcholine. If this is the case, acetylcholine will be
produced by RANKL-treated BMMs and then reduce TRAP-positive cell
formation. However, a previous report demonstrated that acetylcholine did
not affect TRAP-positive cell formation but directly induced apoptosis in
RANKL-treated BMMs cultures [17]. This suggests that acetylcholine is not
produced by RANKL-treated BMMs. To test whether acetylcholine is produced
by RANKL-treated BMMs, we added donepezil in the RANKL-treated BMMs
cultures. Unexpectedly, donepezil did not induce apoptosis in RANKL-treated
Article No~e00013
11 http://dx.doi.org/10.1016/j.heliyon.2015.e00013
2405-8440/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
BMMs at all (Fig. 3D). In contrast, carbamylcholine (CCh) which is the
stable analogue of acetylcholine induced apoptosis (Fig. 3D). These results
suggest that acetylcholine is not accumulated in the culture supernatant of
RANKL-treated BMMs.
[(Fig._3)TD$FIG]
Fig. 3. Id2 upregulation by donepezil-dependent inhibition of osteoclast differentiation and
donepezil does not induce apoptosis in osteoclast. A, The expression of Id2 mRNA in BMMs
with donepezil (0, 0.5 and 5 μg/ml) in the presence of RANKL for 24 h estimated by qPCR
analysis. Data are calculated from three repeated experiments. B, [43_TD$DIFF] he expression of Id2 and c-Fos
protein in BMMs with donepezil (0, 0.5 and 5 μg/ml) in the presence of RANKL for 36 h
estimated by Western blot analysis. Data are calculated from three repeated experiments. C,
Expression of RANK mRNA in BMMs with donepezil (5 mg/ml) for the indicated times estimated
by qPCR analysis. Data are calculated from three repeated experiments. D, Detection of apoptotic
cells in BMMs stimulated by donepezil (5 μg/ml) or carbamylcholine (CCh at 1 μM) in the
presence of RANKL for 48 h. Data are calculated from three repeated experiments. RANKL,
receptor activator of nuclear factor-κB ligand; BMMs, bone marrow macrophages; TRAP,
tartrate-resistant acid phosphatase; Id2, inhibitors of differentiation/DNA binding 2; #, p < 0.05.
Data are expressed as the means ± S.D.
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3.4. Donepezil prevents RANKL-induced bone loss [62_TD$DIFF]in vivo via
suppression of osteoclastic bone resorption
Finally, because donepezil strongly inhibited RANKL-induced osteoclast
differentiation [63_TD$DIFF]in vitro, we examined whether donepezil affects bone mass in
growing wild type mice in a short-term administration and has a preventive effect
on the loss of bone mass in mice which are induced bone loss by short-term
administration of RANKL. Donepezil administration three times for 3 days at 24 h
intervals in 9-week-old mice exhibited high bone mass by inhibiting bone
resorption (Fig. 4A–C). In RANKL-induced model, injections of soluble RANKL
(1 mg/kg) three times at 24 h intervals induced bone loss in 9-week-old male mice
(Fig. 4A–C). Donepezil administration also prevented RANKL-induced bone loss
(Fig. 4A). Donepezil also decreased the number of osteoclasts [64_TD$DIFF]in vivo (Fig. 4B)
and serum concentration of DPD, a marker of bone resorption (Fig. 4C). In
contrast, osteoblastic bone formation was not changed by donepezil administration.
(Supplementary Fig. S4A–C). Donepezil was detected in serum on HPLC in mice
injected with donepezil (Supplementary Fig. S4D). These findings suggest that
donepezil directly prevents bone loss by suppressing osteoclastic bone resorption [65_TD$DIFF]
in vivo.
Supplementary material related to this article is found, in the online version, at
http://dx.doi.org/10.1016/j.heliyon.2015.e00013.
4. Discussion
The present study demonstrates that AChE plays an important role for osteoclast
differentiation and that donepezil inhibits osteoclast differentiation and function [66_TD$DIFF]
in vitro, which may be a cause at least in part for the RANKL-induced bone
loss [67_TD$DIFF]in vivo in mice treated with donepezil. Knockdown of endogenous AChE
resulted in the inhibition of [59_TD$DIFF]NFATc1 mRNA expression and TRAP-positive cell
formation. Furthermore, endogenous AChE mRNA expression was
downregulated by donepezil. These results suggest that the endogenous level of
AChE in BMMs is enhanced by AChE in a positive feedback loop to promote
osteoclast differentiation. RANK mRNA expression was upregulated by AChE
(Supplementary Fig. S2D) and downregulated by donepezil (Fig. 3C). This
suggests that AChE modulates the sensitivity of BMMs to RANKL.
Heat-inactivated AChE did not promote RANKL-induced osteoclast
differentiation (Fig. 1B). This suggests that the enzymatic activity of AChE is
required for the promotion of osteoclast differentiation. Since acetylcholine has
been known to be the target molecule of AChE, we examined the involvement
of acetylcholine in the promotion of osteoclast differentiation by AChE. Bajayo
et al. demonstrated that acetylcholine did not affect TRAP-positive cell
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formation but directly induced apoptosis in RANKL-treated BMMs cultures
[17]. In this context, we expected that donepezil which blocks the activity of
AChE causes accumulation of acetylcholine in the culture supernatant and
subsequently induces apoptosis in RANKL-treated BMMs cultures without
affecting osteoclast differentiation. Surprisingly, we found that donepezil did not
[(Fig._4)TD$FIG]
Fig. 4. Donepezil prevents RANKL-induced bone loss [44_TD$DIFF]in vivo by suppressing osteoclastic bone
resorption. Histomorphometric analyses of mice injected with PBS (n = 6), donepezil (n = 6),
RANKL with PBS (n = 6), or RANKL with donepezil (2 mg/kg) (n = 6). A, (upper panel) von
Kossa staining of mouse vertebra, (lower panel) bone volume/tissue volume (BV/TV; %). B,
osteoclast number/bone perimeter (No.Oc/B.Pm; per 100 mm). C, Serum concentration of DPD
measured by ELISA. Data are calculated from three repeated experiments. PBS, phosphate-buffered
saline; RANKL, receptor activator of nuclear factor-κB ligand; DPD, deoxypyridinoline; ##,
p < 0.01. Data are expressed as the means ± S.D.
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induce TUNEL-positive cells, but inhibited TRAP-positive osteoclast formation
(Fig. 3D, Fig. 2A). This suggests that acetylcholine is not accumulated in
RANKL-treated BMMs cultures. Given these experimental results, the
degradation of acetylcholine appears not to be required for the promotion of
RANKL-induced osteoclast differentiation by AChE. We speculate that AChE
promotes osteoclast differentiation via its enzymatic activity independent of the
degradation of acetylcholine. Further investigation is needed for elucidating the
unknown mechanisms.
From the physiological point of view, the increment of serum AChE
concentration may give rise to detrimental effect for maintaining bone mass.
Since the serum AChE activity is continuously increased with age [26], AChE
may accelerate the risk of bone loss in elderly people. The AChE concentration
in monocytes and macrophages was upregulated under inflammatory conditions.
Thus, it is possible to consider that inflammation promotes bone resorption in
part due to AChE production.
Our study also demonstrates that the inhibitory effect of donepezil on osteoclast
differentiation is accompanied with Id2 upregulation. The Id proteins modulate
RANKL-mediated osteoclastogenesis by inhibiting MITF binding to the promoter
of osteoclast-associated immunoglobulin-like receptor [23]. Other molecules and
compounds which can inhibit osteoclast differentiation with the modulation of Id2
expression have been reported. The small molecule harmine upregulates Id2
expression in parallel with the inhibition of osteoclast differentiation [27].
Interleukin-3 inhibits osteoclast differentiation with sustaining Id2 expression and
downregulating c-Fos expression [28]. Therefore, it is interesting that c-Fos
expression was downregulated during osteoclast differentiation by donepezil
treatment.
It is possible that donepezil simply binds to RANKL and thereby reduces its
bioavailability. However, as our data showed that donepezil reduces RANK
expression of BMMs, we speculate that main contribution against the
inhibitory effect of osteoclast differentiation by donepezil may be due to
reduction of RANK expression. We also consider that the possibility of
RANKL-independent inhibitory effect by donepezil may be small because
donepezil attenuates RANK expression. On the other hand, since we did not
estimate whether donepezil affects RANKL expression of osteoblasts, it is
possible that donepezil modulates RANKL expression of RANKL-producing
cells.
Furuya et al. demonstrated that anti-mouse RANKL-neutralizing monoclonal
antibody significantly increased bone mineral density in the trabecular area on
day 2, day 3, and day 4 in 6-week-old mice with reduction of a serum bone
resorption marker and TRAP-positive cells by histological analysis [29]. This
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report demonstrates that the blockade of RANK-RANKL signaling only 2 days
increases bone mass in growing mice. Consistent with this observation, our
result demonstrated that donepezil significantly increased bone mass in
trabecular area on day 3 in 9-week-old mice with reduction of serum bone
resorption marker and TRAP-positive cells by histological observation. As we
found that donepezil showed inhibitory effect of RANK expression, it is
possible that the blockade of RANK-RANKL signaling by donepezil in
growing mice may result in high bone mass.
Donepezil is the most common medication used for the treatment of Alzheimer's
disease [30]. Patients with Alzheimer's disease have increased risk of serious
falls and show higher incidence of hip fracture and lower hip bone mass [36_TD$DIFF] 31]
[32] [33]. Recently, a case-control study reported that the patients treated with
donepezil were dose-dependently associated with the lower risk of hip fracture
independently of falling [5]. Whether donepezil is a bone protective drug in
patients with Alzheimer's disease is an interesting clinical project, but this
hypothesis needs further basic as well as clinical investigations.
In conclusion, AChE plays a novel function in osteoclastogenesis directly.
Donepezil prevents RANKL-induced bone loss. Further experiments are
necessary to elucidate the molecular mechanism of AChE in osteoclastogenesis.
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